Tempus AI (TEM) News Today

Tempus AI, Inc. (NASDAQ: TEM) is getting attention from investors after a mix of bullish research commentary and a fresh business update from a subsidiary, even as analysts remain cautious overall. The stock appears to be benefiting from optimism around its AI-driven healthcare data platform and improving profitability trends.

• Positive Sentiment: Several recent pieces argue that Tempus AI’s valuation has become more attractive after a sharp compression, with one Seeking Alpha note saying the risk-reward setup has improved as revenue growth remains strong and operating losses narrow toward breakeven. Tempus AI: The Compression Has Outrun The Business - Upgrading To Buy
• Positive Sentiment: Another bullish take highlighted Tempus AI’s data moat, large proprietary dataset, and expanding partnerships in healthcare AI, reinforcing the idea that the company could build a high-margin “data machine” over time. Tempus AI: A Unique AI Business Model With Asymmetric Upside
• Positive Sentiment: Ambry Genetics, a Tempus AI subsidiary, reported peer-reviewed research showing its ExomeReveal RNA testing may improve diagnostic clarity in exome testing, which could support Tempus’s diagnostics and genomics growth narrative. Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal RNA Testing Can Improve Diagnostic Clarity in Exome Testing
• Neutral Sentiment: Tempus AI presented at the Goldman Sachs 47th Annual Global Healthcare Conference, which keeps management visible to investors but did not include any major new guidance in the item provided. Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Brokerage coverage summaries indicated Tempus AI’s consensus rating remains “Hold,” suggesting analysts are still waiting for clearer proof of sustained profitability and execution. Tempus AI, Inc. Given Average Rating of Hold by Brokerages
• Negative Sentiment: Short-interest data showed no meaningful change in bearish positioning, but the report was unusual and did not provide evidence of a stronger short squeeze setup or improving sentiment from skeptics. Tempus AI, Inc. Given Consensus Recommendation of Hold by Analysts

Overall, TEM is being supported by bullish commentary around its AI data platform, revenue growth, and narrowing losses, while the “Hold” analyst backdrop suggests the market still wants more proof before assigning a higher multiple.